-
-
-
-
-
-
-
ChromaDex (CDXC) Tops Q3 EPS by 1c
-
-
-
-
-
-
-
ChromaDex (CDXC) Reports Findings from Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson’s Disease (PD)
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

